May 14, 2020 / 6:44 AM / 19 days ago

BRIEF-Verona Pharma Announces U.S. FDA Response To End-Of-Phase 2 Briefing Package For Ensifentrine In COPD

May 14 (Reuters) - Verona Pharma PLC:

* VERONA PHARMA ANNOUNCES FDA RESPONSE TO END-OF-PHASE 2 BRIEFING PACKAGE FOR ENSIFENTRINE IN COPD AND OUTLINES PHASE 3 ENHANCE CLINICAL PROGRAM

* RECEIVED WRITTEN COMMENTS FROM U.S. FDA IN RESPONSE TO ITS END-OF-PHASE 2 BRIEFING PACKAGE FOR NEBULIZED ENSIFENTRINE

* RESPONSE SUPPORTS VERONA PHARMA PROGRESSING WITH ITS PLANNED PHASE 3 CLINICAL PROGRAM

* IS ACCELERATING PREPARATIONS FOR PHASE 3 CLINICAL PROGRAM TO START LATER IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below